Brings to all projects over 40 years of industry experience from leading small, medium and large pharmaceutical companies
Dan Vickery, M.B.A., Ph.D.
Founder & President
Carolyn Myers, M.B.A., Ph.D.
Dr. Vickery is a pharmaceutical executive with general management, business development and commercialization expertise. He is the founder and President of BioEnsemble, which was established in 2005. He provides consulting services to help promising technologies and companies enhance their strategic direction to find development partners and sources of funding.
Dr. Vickery is currently on the board of Urigen Pharmaceuticals, Inc. and has also acted as CEO, President, Chairman and managing consultant for that company. He is an advisory board member of the Centre for Molecular Medicine and Therapeutics and a board member of Interstial Cystitis Association. He is also a President's Circle member of the American Association for the Advancement of Science and a member of the Licensing Executive’s Society.
Prior to starting his consulting practice in 2005, he held a senior business development position at Mylan, overseeing their Branded Products and Drug Delivery divisions, during which he focused on transactions for Drug Delivery products and in/out-licensing of branded products.
Prior to joining Mylan, Dr. Vickery had worldwide commercial development responsibility at Pharmacia for the therapeutic areas of Urology, Women’s Health Care, and Sexual Dysfunction.
He also has significant experience in drug/clinical development, and regulatory having lead the Regulatory Affairs department at Parke-Davis division, Warner-Lambert, during the time that Lipitor was approved and launched.
Dr. Myers is an accomplished pharmaceutical executive with extensive experience optimizing productivity, creating value and increasing profitability. She has broad general management, business development and commercial expertise in US and global markets, and is adept at developing strategic plans and translating them into actionable objectives that drive performance and growth.
She has been an advisor for BioEnsemble since 2006 and became a Principal in 2017. She is a member of Mid Atlantic Bio Angels, a mentor for Weill Cornell's Bench to Bedside Initiative for young entrepreneurs, a member of the Licensing Executive's Society and a board member at the Centre for Molecular Medicine and Therapeutics at UBC.
Before joining BioEnsemble, Dr. Myers led Global Alliance Management & International Brand Business Development at Allergan, leading an Alliance Management team that managed over 150 partners, representing a sizeable portion of Allergan’s promoted and development product portfolio. In her BD role, she led development of BD strategy, and directed the evaluation and ultimate negotiation of several BD opportunities. Earlier, Dr. Myers led CNS marketing where she managed the marketing team responsible for CNS brands with $2.5B in annual sales (about 75% of company revenue in 2011).
Previously, Dr. Myers held several senior positions at Mylan, including President at Dey Labs, Mylan’s $600M branded business unit where she had P&L responsibility and managed the entire business unit. Also, she held the position of President of Mylan Technologies, a developer and manufacturer of generic and branded patches. A key achievement was leading the prioritization of the pipeline and FDA approval of three key prioritized products. She also led, Branded BD & Strategic Marketing, working closely with senior leadership to enhance Mylan’s branded business strategy.
In addition, Dr. Myers has extensive sales & marketing experience from the numerous positions she held at Pharmacia.